Default company panoramic image
Logo

cell constraint & cancer

Cell Constraint & Cancer develops a disruptive innovation in Oncology: 2 medical devices. Proof of Concept in 2012. P. of Efficacy in 13/14.

  • Stage Product In Development
  • Industry Medical Devices and Equipment
  • Location Arles, PACA, France
  • Currency EUR
  • Founded March 2009
  • Employees 2
  • Website cellconstraintcancer.com

Company Summary

This disruptive innovation is an application of Physical Biology. A patent (EP 13176364) protects the modification of the cancerous phenotype of a tissue by mechanical signals. Magnetizable particles are positionned around (Not in) a tumor and submitted to a gradient of magnetic field. Proof of Concept in vivo obtained in 2012. The concept in vitro 3D is validated in the literature (M Paszek 2005, F Montel 2011).

Team

  • Default avatar
    Rémy Brossel
    MD

    Physicist and Physician (Oncologist). Settled and ran a CRO before being the CEO of CC&C.

  • Default avatar
    Jean Marc Guinebretière
    MD

    Pathologist with Institut Curie France. He is in charge of the analysis of the tumors in the animal models

Advisors

  • Default avatar
    P Callet, Paris
    Lawyer
    Unconfirmed
    Default avatar
    G Husson, Essey les Nancy
    Accountant
    Unconfirmed

Previous Investors

  • Default avatar
    59 Shareholders
    Unconfirmed